Hanmi Pharm stock gains after Samsung Securities raises target

Published on 09/21/2026 at 22:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hanmi Pharm stock gained support after Samsung Securities raised its target to KRW 650,000 on September 21, 2026. First-half revenue rose 14.4 percent to KRW 860.2 billion and operating profit jumped 54.6 percent.

Hanmi Pharm, KR7128940004, Illustration mit AI erstellt.

Hanmi Pharm stock (KR7128940004) gained support after Samsung Securities raised its target to KRW 650,000 from KRW 610,000 on September 21, 2026, while the shares closed at KRW 505,000 and rose KRW 2,000, or 0.40 percent, on the day. The move came as the stock drew fresh attention from target-price upgrades and pipeline updates on obesity drugs.

Targets and pipeline

According to Econovill on September 21, 2026, Samsung Securities lifted its 2026 sales forecast for Hanmi Pharm to KRW 1.78 trillion and operating profit to KRW 377.0 billion, with an operating margin of 21.2 percent. The same report said analyst Seo Geun-hee raised the target price to KRW 650,000 from KRW 610,000.

The report also tied the higher view to HM17321, which it said won a technology transfer deal with Genentech in August, and to the approval process for efpeglenatide, Hanmi's long-acting GLP-1 obesity drug. That combination matters because the market is now pricing both near-term earnings and the obesity pipeline at the same time.

First-half numbers

According to Econovill on September 21, 2026, Hanmi Pharm reported first-half revenue of KRW 860.2 billion, up 14.4 percent year on year, operating profit of KRW 184.7 billion, up 54.6 percent, and net profit of KRW 135.2 billion, up 54.2 percent. R&D spending rose to KRW 125.5 billion from KRW 106.1 billion, an increase of 18.3 percent.

Those figures show that the operating base is still expanding even after the stock's strong rerating. For investors, the comparison is clear: revenue growth was mid-teens, but profit growth was more than three times faster.

Market backdrop

At KRW 505,000 on September 21, 2026, the share price sat below the KRW 650,000 target and above the first-half earnings base that helped drive the latest rerating. The gap leaves the next catalyst tied to execution on obesity drugs, licensing income and the pace of margin expansion.